Daphne Zohar, Founder and CEO of Seaport Therapeutics, shares her deep insights into the biotech landscape. She discusses the complex challenges of drug development, particularly in psychiatric treatments, while shedding light on high failure rates and funding obstacles. Daphne explores the intersection of tech and biotech investment, emphasizing the regulatory hurdles and the implications of the Biosecure Act on innovation. She advocates for greater transparency in the industry and the necessity of political support to drive progress in patient care.

Lizzy Lawrence, STAT’s FDA reporter, joins biotech experts Brian Skorney and Daphne Zohar to discuss the impact of a potential Trump presidency on the FDA and the biotech industry. They delve into concerns over regulatory changes, FDA leadership stability, and investor sentiments regarding vaccines and antivirals. The conversation also explores how immigration policies may affect talent acquisition in biotech. Finally, they analyze the Inflation Reduction Act’s effects on drug development and pricing, shedding light on innovation in a politically charged landscape.

Biotech Hangout hosts discuss Biden's capital gains tax proposal, FTC's non-compete ban, Q1 earnings reports, Acrivon's oncology data, ImmunityBio's FDA approval, and financings like Xaira Therapeutics $1B raise. They also debate liked vs unliked CEOs and delve into innovative biotech approaches in depression and obesity treatment, as well as biotech deals and investments.